APA

Guo S., Tang L., Zhang L., Chen Q., Liu L., Guo L., Mo H., Luo D., Huang P., Xiang Y., Sun R., Chen M., Wang L., Lv X., Zhao C., Guo X., Cao K., Qian C., Zeng M., Bei J., Hong M., Shao J., Sun Y., Ma J. & Mai H. (20160831). The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. : BMC cancer.

Chicago

Guo Shan-Shan, Tang Lin-Quan, Zhang Lu, Chen Qiu-Yan, Liu Li-Ting, Guo Ling, Mo Hao-Yuan, Luo Dong-Hua, Huang Pei-Yu, Xiang Yan-Qun, Sun Rui, Chen Ming-Yuan, Wang Lin, Lv Xing, Zhao Chong, Guo Xiang, Cao Ka-Jia, Qian Chao-Nan, Zeng Mu-Sheng, Bei Jin-Xin, Hong Ming-Huang, Shao Jian-Yong, Sun Ying, Ma Jun and Mai Hai-Qiang. 20160831. The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. : BMC cancer.

Harvard

Guo S., Tang L., Zhang L., Chen Q., Liu L., Guo L., Mo H., Luo D., Huang P., Xiang Y., Sun R., Chen M., Wang L., Lv X., Zhao C., Guo X., Cao K., Qian C., Zeng M., Bei J., Hong M., Shao J., Sun Y., Ma J. and Mai H. (20160831). The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. : BMC cancer.

MLA

Guo Shan-Shan, Tang Lin-Quan, Zhang Lu, Chen Qiu-Yan, Liu Li-Ting, Guo Ling, Mo Hao-Yuan, Luo Dong-Hua, Huang Pei-Yu, Xiang Yan-Qun, Sun Rui, Chen Ming-Yuan, Wang Lin, Lv Xing, Zhao Chong, Guo Xiang, Cao Ka-Jia, Qian Chao-Nan, Zeng Mu-Sheng, Bei Jin-Xin, Hong Ming-Huang, Shao Jian-Yong, Sun Ying, Ma Jun and Mai Hai-Qiang. The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. : BMC cancer. 20160831.